BridgeBio Oncology Therapeutics Inc.
BBOTAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Sep 9, 2026 | Raymond James | Sean McCutcheon | $22.00(+158%) | $8.52 | TheFly |
| Sep 9, 2026 | Stifel Nicolaus | $15.00(+69%) | $8.86 | TheFly | |
| Sep 9, 2026 | Canaccord Genuity | $20.00(+126%) | $8.86 | TheFly | |
| May 11, 2026 | Canaccord Genuity | John Newman | $23.00(+200%) | $7.66 | TheFly |
| Feb 10, 2026 | Stifel Nicolaus | Laura Prendergast | $23.00(+112%) | $10.84 | TheFly |
| Jan 9, 2026 | Raymond James | $24.00(+80%) | $13.30 | TheFly | |
| Jan 8, 2026 | Morgan Stanley | $18.00(+39%) | $12.92 | TheFly | |
| Dec 5, 2025 | Morgan Stanley | $20.00(+73%) | $11.54 | TheFly | |
| Sep 17, 2025 | Leerink Partners | $25.00(+132%) | $10.79 | TheFly | |
| Sep 15, 2025 | H.C. Wainwright | Robert Burns | $27.00(+177%) | $9.73 | TheFly |
| Sep 4, 2025 | Oppenheimer | $23.00(+128%) | $10.08 | TheFly | |
| Aug 15, 2025 | Piper Sandler | Biren Amin | $21.00(+116%) | $9.70 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Morgan Stanley | maintain | Overweight | Oct 21, 2026 |
| Oppenheimer | maintain | Outperform | Oct 20, 2026 |
| JP Morgan | maintain | Overweight | Sep 11, 2026 |
| Leerink Partners | maintain | Outperform | Sep 10, 2026 |
| Canaccord Genuity | maintain | Buy | Sep 9, 2026 |
| Raymond James | maintain | Outperform | Sep 9, 2026 |
| Stifel | maintain | Buy | Sep 9, 2026 |
| Wedbush | maintain | Outperform | Sep 9, 2026 |
| JP Morgan | maintain | Overweight | Aug 14, 2026 |
| HC Wainwright & Co. | maintain | Buy | Mar 6, 2026 |
| Wedbush | maintain | Outperform | Dec 11, 2025 |
| Wedbush | maintain | Outperform | Nov 25, 2025 |
| Oppenheimer | maintain | Outperform | Nov 13, 2025 |
Earnings History
Next report: Nov 11, 2026 · EPS est. $-0.69| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 11, 2026 | $-0.71 | $-0.56 | — | — |
| May 12, 2026 | $-0.48 | $-0.51 | — | — |
| Mar 5, 2026 | $-0.49 | $-0.63 | — | — |
| Nov 12, 2025 | $-1.03 | $-0.38 | — | — |
| Aug 1, 2025 | $-50.34 | $-42.45 | — | — |
| May 15, 2025 | $-52.15 | — | — | — |
| Mar 11, 2025 | $0.12 | — | — | — |
| Nov 14, 2024 | $-0.74 | — | — | — |
News
BridgeBio Oncology Therapeutics is rated Speculative Buy, with a risk-adjusted valuation of $3.76 per share, implying 33% upside. BBOT's pipeline, led by BBO-11818, targets multiple KRAS mutations and offers potential differentiation over existing KRAS G12C inhibitors. Recent strategic shifts and clinical updates triggered a 68% decline in BBOT's stock, reflecting concerns about commercial scope and execution.
SOUTH SAN FRANCISCO, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded an inducement grant on October 10, 2026, under BBOT's 2025 Inducement Plan as a material inducement to the employment of one individual hired by BBOT in September 2026.
BridgeBio Oncology Therapeutics, Inc (NASDAQ: BBOT - Get Free Report) has earned an average rating of "Moderate Buy" from the ten analysts that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating and nine have issued a buy rating on the company. The average 1-year price target
BridgeBio Oncology Therapeutics, Inc (NASDAQ: BBOT - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the ten ratings firms that are presently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation and nine have issued a buy recommendation on the company. The average 12
SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced new clinical data for KRASG12C inhibitor BBO-8520 and the strategic prioritization of (i) BBO-8520 in combination with checkpoint inhibitor in 2L+ KRASG12C inhibitor-experienced non-small cell lung cancer (NSCLC) patients and (ii) BBO-11818 and BBO-10203 combinations in KRAS-m…
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced that members of its leadership team will participate in upcoming investor conferences.
SOUTH SAN FRANCISCO, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced it awarded inducement grants on August 10, 2026 under BBOT's 2025 Inducement Plan as a material inducement to the employment of two individuals hired by BBOT in July 2026.
Continued to advance monotherapy and combination cohorts for all clinical programs Initiated dosing of BBO-11818 in combination with cetuximab and after the end of the quarter, initiated dosing of BBO-11818 in combination with BBO-10203 Presented preclinical data at AACR highlighting the potency and activity of BBO-11818 in KRAS mutant tumor models and the efficacy of BBO-10203 in combination with tucatinib and trastuzumab in HER2amp models Cash runway expected to fund operations into 2028 SOUTH…